ND Committee Review
Internal Medical Policy Committee 11-23-2021-
Effective January 1, 2022
- Adopted Medicaid Expansion specific policy
Internal Medical Policy Committee 11-29-2022 -
Effective January 1, 2023
- Added
preferred products,
and
- Updated
initial criteria,
and
- Updated
reauthorization criteria,
and
- Updated
experimental/investigational statement
Internal Medical Policy Committee 11-15-2023 -
Effective January 1, 2024
- Removed
trial agents criteria for MS
Internal Medical Policy Committee 3-19-2024
Effective April 01, 2024
- Added
natalizumab-sztn (Tyruko), Q5134, to the policy
Internal Medical Policy Committee 03-11-2025
Effective April 01, 2025
- Updated
Crohn's Disease initial criteria required based on the DHHS PDL Version 2025.2